SIRT5 and pancreatic neoplasm: An additional 1,4-dihydropyridine Sirt5 activator, MC3138, did not impact Sirt1/3 deacetylase activity at a concentration of 100 μM in vitro and demonstrated on-target cellular Sirt5 activation via decreased acylation of the Sirt5 substrate glutamate oxaloacetate transaminase 1 (GOT1) in pancreatic cancer cell lines [101].